Cell entry mechanisms of SARS-CoV-2
- PMID: 32376634
- PMCID: PMC7260975
- DOI: 10.1073/pnas.2003138117
Cell entry mechanisms of SARS-CoV-2
Abstract
A novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) is causing the global coronavirus disease 2019 (COVID-19) pandemic. Understanding how SARS-CoV-2 enters human cells is a high priority for deciphering its mystery and curbing its spread. A virus surface spike protein mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to its receptor human ACE2 (hACE2) through its receptor-binding domain (RBD) and is proteolytically activated by human proteases. Here we investigated receptor binding and protease activation of SARS-CoV-2 spike using biochemical and pseudovirus entry assays. Our findings have identified key cell entry mechanisms of SARS-CoV-2. First, SARS-CoV-2 RBD has higher hACE2 binding affinity than SARS-CoV RBD, supporting efficient cell entry. Second, paradoxically, the hACE2 binding affinity of the entire SARS-CoV-2 spike is comparable to or lower than that of SARS-CoV spike, suggesting that SARS-CoV-2 RBD, albeit more potent, is less exposed than SARS-CoV RBD. Third, unlike SARS-CoV, cell entry of SARS-CoV-2 is preactivated by proprotein convertase furin, reducing its dependence on target cell proteases for entry. The high hACE2 binding affinity of the RBD, furin preactivation of the spike, and hidden RBD in the spike potentially allow SARS-CoV-2 to maintain efficient cell entry while evading immune surveillance. These features may contribute to the wide spread of the virus. Successful intervention strategies must target both the potency of SARS-CoV-2 and its evasiveness.
Keywords: ACE2 receptor; COVID-19; SARS-CoV; SARS-CoV-2; proprotein convertase furin.
Copyright © 2020 the Author(s). Published by PNAS.
Conflict of interest statement
The authors declare no competing interest.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig01.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig02.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig03.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig04.gif)
![Fig. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig05.gif)
![Fig. 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7260975/bin/pnas.2003138117fig06.gif)
Similar articles
-
Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).Mini Rev Med Chem. 2021;21(6):689-703. doi: 10.2174/1389557520666201117111259. Mini Rev Med Chem. 2021. PMID: 33208074 Review.
-
Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.ACS Nano. 2020 Aug 25;14(8):10616-10623. doi: 10.1021/acsnano.0c04798. Epub 2020 Aug 4. ACS Nano. 2020. PMID: 32806067
-
Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.Infection. 2020 Oct;48(5):665-669. doi: 10.1007/s15010-020-01486-5. Epub 2020 Jul 31. Infection. 2020. PMID: 32737833 Free PMC article. Review.
-
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15. Cell Mol Immunol. 2020. PMID: 32415260 Free PMC article.
-
Structural basis of receptor recognition by SARS-CoV-2.Nature. 2020 May;581(7807):221-224. doi: 10.1038/s41586-020-2179-y. Epub 2020 Mar 30. Nature. 2020. PMID: 32225175 Free PMC article.
Cited by
-
Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects.Mar Life Sci Technol. 2024 Feb 21;6(2):280-297. doi: 10.1007/s42995-023-00215-9. eCollection 2024 May. Mar Life Sci Technol. 2024. PMID: 38827130 Review.
-
Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.Heliyon. 2024 May 19;10(10):e31392. doi: 10.1016/j.heliyon.2024.e31392. eCollection 2024 May 30. Heliyon. 2024. PMID: 38826759 Free PMC article.
-
Structural, dynamic behaviour, in-vitro and computational investigations of Schiff's bases of 1,3-diphenyl urea derivatives against SARS-CoV-2 spike protein.Sci Rep. 2024 Jun 1;14(1):12588. doi: 10.1038/s41598-024-63345-9. Sci Rep. 2024. PMID: 38822113 Free PMC article.
-
A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.PLoS One. 2024 May 31;19(5):e0304534. doi: 10.1371/journal.pone.0304534. eCollection 2024. PLoS One. 2024. PMID: 38820303 Free PMC article.
-
Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication.EMBO Rep. 2024 Jul;25(7):2974-3007. doi: 10.1038/s44319-024-00164-z. Epub 2024 May 30. EMBO Rep. 2024. PMID: 38816514 Free PMC article.
References
-
- Lee N. et al. ., A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–1994 (2003). - PubMed
-
- Wu F., et al. , Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv:2020.2003.2030.20047365 (20 April 2020).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous